Emerging Trends in the Pathogenesis, Diagnosis, and Management of Human Metapneumovirus-Associated Respiratory Infections

Introduction: Human Metapneumovirus is a significant respiratory pathogen causing infections across all age groups, particularly in young children, immunocompromised individuals, and the elderly. Despite its clinical relevance, there are currently no approved vaccines or specific antiviral treatments for Human Metapneumovirus, necessitating further research into therapeutic and preventive strategies. Methods: A systematic literature review was conducted using peer-reviewed journals, clinical trials, and recent studies focusing on Human Metapneumovirus infection. Data were extracted and analyzed to evaluate the effectiveness of antiviral therapies, monoclonal antibodies, immunomodulators, and vaccine candidates. Results: Studies indicate that Human Metapneumovirus primarily targets the respiratory epithelium, triggering immune responses that contribute to both viral clearance and disease pathogenesis. Investigational therapies, including fusion inhibitors and protease inhibitors, show promise but require further validation. Immunomodulatory agents and herbal remedies may offer supportive benefits, but their efficacy against Human Metapneumovirus remains unproven. Advances in vaccine development are ongoing, with several candidates in preclinical and early clinical stages. Discussion: HMPV continues to pose a substantial public health burden due to its seasonal outbreaks, clinical similarity to other respiratory viruses, and absence of specific therapies. The virus evades immune responses via multiple mechanisms, contributing to disease severity, particularly in vulnerable populations. Although supportive care is currently the mainstay, emerging antivirals and vaccines may offer future solutions. Improved diagnostic access, public awareness, and targeted research are essential for controlling HMPV infections. Conclusion: Human Metapneumovirus continues to pose a public health challenge due to the lack of targeted treatments and vaccines. Ongoing research into antiviral agents, monoclonal antibodies, and vaccines is critical for effective disease management. Further clinical trials are needed to establish safe and effective therapeutic options.